Aubrey Rankin's Insider Trades & SAST Disclosures
Aubrey Rankin's most recent trade in Revance Therapeutics Inc was a trade of 1,372 Common Stock done at an average price of $15.8 . Disclosure was reported to the exchange on March 15, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Aubrey Rankin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | Aubrey Rankin | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.79 per share. | 15 Mar 2022 | 1,372 | 94,091 (0%) | 0% | 15.8 | 21,664 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Purchase of securities on an exchange or from another person at price $ 14.43 per share. | 03 Dec 2021 | 30,000 | 95,463 (0%) | 0% | 14.4 | 432,876 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 26.34 per share. | 15 Aug 2021 | 9,364 | 65,463 (0%) | 0% | 26.3 | 246,659 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.02 per share. | 15 Aug 2021 | 4,949 | 74,827 (0%) | 0% | 26.0 | 128,773 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 29.72 per share. | 26 Jul 2021 | 55,382 | 355,943 (0%) | 0% | 29.7 | 1,645,953 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 28.50 per share. | 05 Apr 2021 | 2 | 411,325 (0%) | 0% | 28.5 | 57 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 25.43 per share. | 04 Mar 2021 | 33,119 | 411,327 (0%) | 0% | 25.4 | 842,216 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 21,540 | 21,540 | - | - | Employee Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 11,905 | 79,776 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 25.95 per share. | 01 Feb 2021 | 33,119 | 444,446 (0%) | 0% | 25.9 | 859,438 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 23.85 per share. | 30 Nov 2020 | 33,119 | 510,684 (0%) | 0% | 23.8 | 789,888 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 26.15 per share. | 29 Oct 2020 | 33,119 | 543,803 (0%) | 0% | 26.1 | 865,949 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Sale of securities on an exchange or to another person at price $ 26.18 per share. | 28 Sep 2020 | 33,119 | 576,922 (1%) | 0% | 26.2 | 867,055 | Common Stock |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 610,041 | 610,041 (1%) | 1% | - | Common Stock | |
| Revance Therapeutics Inc | Aubrey Rankin | Director, President, Innovation & Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 57,251 | 67,871 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges